Gil Roth07.09.10
Slowing sales, mega-mergers, generic implosions and whipsawing exchange rates have caused some shakeups within the Top 20 Pharma ranks. The loss of Wyeth and Schering-Plough, coupled with Roche’s defection to the Biopharma list, led us to find several new players: Otsuka, Gilead and Mylan.
I’m not sure how significant it is that half of “the second tier” (companies 11-20) are based in Japan, but I find it interesting that Gilead (#19) is the only non-generic U.S. pharma company in that tier. (Just below the cutoff line, companies #21 and #22 are Dutch and Japanese, respectively.) I also find it interesting that Teva has revenue goals that could propel it into the top 7 ranks in the next few years. Aim high, pharma!
Based on 2009 pharma revenues.
Note: In all Top Company profiles, dollar amounts are in millions.
Editor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe
I’m not sure how significant it is that half of “the second tier” (companies 11-20) are based in Japan, but I find it interesting that Gilead (#19) is the only non-generic U.S. pharma company in that tier. (Just below the cutoff line, companies #21 and #22 are Dutch and Japanese, respectively.) I also find it interesting that Teva has revenue goals that could propel it into the top 7 ranks in the next few years. Aim high, pharma!
—Gil Y. Roth, Editor
| Top 20 Pharmaceutical Companies | ||
| 01 | Pfizer | $45,448 |
| 02 | Sanofi-Aventis | $40,871 |
| 03 | Novartis | $38,455 |
| 04 | GlaxoSmithKline | $36,746 |
| 05 | AstraZeneca | $31,905 |
| 06 | Merck & Co. | $26,929 |
| 07 | Johnson & Johnson | $22,520 |
| 08 | Eli Lilly & Co. | $20,629 |
| 09 | Bristol-Myers Squibb | $18,808 |
| 10 | Abbott Laboratories | $16,486 |
| 11 | Takeda Chem. Ind. | $14,204 |
| 12 | Boehringer-Ingelheim | $14,027 |
| 13 | Teva Pharma | $13,814 |
| 14 | Bayer Schering | $13,344 |
| 15 | Astellas | $10,509 |
| 16 | Daiichi-Sankyo | $9,757 |
| 17 | Eisai | $8,441 |
| 18 | Otsuka | $7,717 |
| 19 | Gilead Sciences | $6,469 |
| 20 | Mylan | $5,015 |
Based on 2009 pharma revenues.
Note: In all Top Company profiles, dollar amounts are in millions.
Contributors
Editor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe
All profiles written by Gil Roth, except Astellas and Daiichi-Sankyo, by Kristin Brooks.
The Lowe Down capsules written by Derek Lowe
All pipeline information compiled by Kristin Brooks
Sales information compiled by Gil Roth
Visit our Top 10 Biopharma companies report!
Back to the July/August 2010 issue
